Hu Wenyi, Chu Tiancheng, Liao Huan, Wang Wei, Ha Jason, Kiburg Katerina, Zhang Xiayin, Shang Xianwen, Huang Yu, Zhang Xueli, Tang Shulin, Hu Yijun, Yu Honghua, Yang Xiaohong, He Mingguang, Zhu Zhuoting
Department of Ophthalmology, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Guangzhou, China.
Centre for Eye Research Australia, Ophthalmology, University of Melbourne, Melbourne, Australia.
J Alzheimers Dis Rep. 2024 Jul 23;8(1):1093-1104. doi: 10.3233/ADR-230154. eCollection 2024.
Previous studies found that visual impairment (VI) is associated with higher risk of cognitive impairment, but the molecular basis of these conditions is unknown.
We aim to compare the metabolite associations of VI and cognitive impairment.
The study population with comprehensive measurements was derived from the UK Biobank study. Visual acuity worse than 0.3 logMAR units were defined as VI. Failure in one or more of the four cognitive tests was defined as cognitive impairment. A panel of 249 metabolites was measured using a nuclear magnetic resonance metabolites profiling platform. Logistic regression models were applied to compare metabolite associations with VI and cognitive impairment.
23,775 participants with complete data on visual acuity, cognitive tests and metabolomics, and without a history of neurological disorders at baseline were included. After adjusting for confounding factors, VI was significantly associated with cognitive impairment (odds ratio[OR] = 1.49, 95% confidence interval [CI]: 1.27-1.74, < 0.001). After multiple testing correction ( < 9×10), five metabolites including the ratio of omega-6 to omega-3 fatty acids (FAs) (OR = 1.18[1.10-1.27]), ratio of omega-3 to total FAs (OR = 0.84[0.77-0.91]), ratio of docosahexaenoic acid (DHA) to total FAs (OR = 0.86[0.80-0.94]), DHA (OR = 0.85[0.78-0.92]), and omega-3 FAs (OR = 0.84[0.77-0.91]) were uniquely associated with VI. Glycoprotein acetyls (OR = 1.06[1.03-1.10]) and alanine (OR = 0.95[0.92-0.98]) were exclusively associated with cognitive impairment. Albumin was identified as the common metabolite shared by the two phenotypes (OR = 0.90[0.85-0.95] for VI, and 0.95[0.92-0.98]) for cognitive impairment).
We identified distinct and overlapping metabolites associated with VI and cognitive impairment, unveiling their distinct metabolic profiles and potential common pathophysiology.
先前的研究发现，视力障碍（VI）与认知障碍风险较高有关，但这些情况的分子基础尚不清楚。
我们旨在比较VI和认知障碍的代谢物关联。
具有全面测量数据的研究人群来自英国生物银行研究。视力低于0.3 logMAR单位被定义为VI。四项认知测试中一项或多项未通过被定义为认知障碍。使用核磁共振代谢物谱平台测量一组249种代谢物。应用逻辑回归模型比较代谢物与VI和认知障碍的关联。
纳入了23775名在基线时具有完整视力、认知测试和代谢组学数据且无神经系统疾病史的参与者。在调整混杂因素后，VI与认知障碍显著相关（优势比[OR]=1.49，95%置信区间[CI]：1.27-1.74，P<0.001）。经过多重检验校正（P<9×10）后，包括ω-6与ω-3脂肪酸（FAs）的比率（OR=1.18[1.10-1.27]）、ω-3与总FAs的比率（OR=0.84[0.77-0.91]）、二十二碳六烯酸（DHA）与总FAs的比率（OR=0.86[0.80-0.94]）、DHA（OR=0.85[0.78-0.92]）和ω-3 FAs（OR=0.84[0.77-0.91]）在内的五种代谢物与VI独特相关。糖蛋白乙酰化物（OR=1.06[1.03-1.10]）和丙氨酸（OR=0.95[0.92-0.98]）仅与认知障碍相关。白蛋白被确定为两种表型共有的代谢物（VI的OR=0.90[0.85-0.95]，认知障碍的OR=0.95[0.92-0.98]）。
我们确定了与VI和认知障碍相关的不同和重叠的代谢物，揭示了它们不同的代谢谱和潜在的共同病理生理学。
